key: cord-0886466-nthw9792
authors: Li, Willis; Li, Jinghong; Wei, Qi; McCowen, Karen; Xiong, Wei; Liu, Jiao; Jiang, Wenlijun; Thomas, Robert; Hepokoski, Mark; He, Ming; Shyy, John; Malhotra, Atul; Xiong, Nian
title: Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus
date: 2021-03-26
journal: Res Sq
DOI: 10.21203/rs.3.rs-287308/v1
sha: 8d183c98caace955a39c1c25dc1863cdf781d097
doc_id: 886466
cord_uid: nthw9792

Type 2 diabetes mellitus (T2DM) is a strong risk factor for complications of coronavirus disease 2019 (COVID-19). The effect of T2DM medications on COVID-19 outcomes remains unclear. In a retrospective analysis of a cohort of 131 patients with T2DM hospitalized for COVID-19 in Wuhan, we have previously found that metformin use prior to hospitalization is associated with reduced mortality. Here we continue to investigate the effects of inpatient use of T2DM medications, including metformin, acarbose, insulin, and sulfonylureas, on the mortality of COVID-19 patients with T2DM during hospitalization. We found that patients using metformin and acarbose, alone or both together, after admission were significantly more likely to survive than those who did not use either metformin or acarbose. Thus, our analyses suggest that inpatient use of metformin and acarbose together or alone during hospitalization should be studied in randomized trials.

Introduction COVID-19 has had devastating consequences for many patients globally. At present remdesivir and dexamethasone are the only proven therapies 1, 2 ; thus, therapeutic advances are still required. A number of risk factors for COVID-19 have been reported including COPD, diabetes, obesity, advanced age, hypertension and other factors [3] [4] [5] . The elucidation of mechanisms underlying these risk factors may have bene ts for strati cation of high risk patients and may help to guide pharmacological targets for a icted patients.

Regarding diabetes, the optimal therapy from the perspective of COVID-19 is unclear. We have recently reported an association between pre-hospitalization metformin use and improved risk of mortality, leading us to consider the impact of inpatient pharmacotherapy 6 . Inpatient therapy for glucose control in the US typically involves discontinuation of oral agents upon admission and initiation of insulin therapy 7 .

However, in some countries, including China, oral agents are used in some cases preferentially even in the inpatient setting.

Typically, oral agents are continued after hospitalization and the doses are adjusted according to guidelines, similar to the outpatient settings 8 . We and others have previously reported on the risks and bene ts of inpatient glycemic control 9, 10 ; however, the best strategy to apply to COVID-19 patients remains unclear. In theory insulin may be bene cial as it could achieve glucose control effectively and avoid hyperglycemia-related complications such as immunosuppression and oxidative stress. On the other hand, some oral agents such as metformin may activate the AMP-activated protein kinase (AMPK), which has important effects on autophagy 11 . Acarbose is an alpha-glucosidase inhibitor, which serves to delay glucose absorption and thus reduce the post-prandial insulin spike 12 . Acarbose has been shown to have potentially important effects on the gut microbiome although the impact of these changes is unclear 13 . Acarbose is a commonly used diabetes medication in China for post-prandial glucose control due to the relatively high-carbohydrate diets.

Based on this conceptual framework, we sought to test the hypothesis that oral agents would have differential effects on COVID-19 inpatients.

Speci cally, we tested whether metformin and acarbose use were associated with improved outcomes as compared to insulin therapy in COVID-19 inpatients in China. Based on the pace of the pandemic, we were unable to perform a randomized trial, but rather conducted an observational study to help inform subsequent research.

131 patients with COVID-19 pneumonia and T2DM hospitalized in Wuhan Red Cross Hospital (WRCH) in Wuhan, China, from January 23, 2020 to March 19, 2020 were included. The same patient cohort has been previously reported for pre-hospital medication use 6 . COVID-19 was diagnosed using reverse transcription polymerase chain reaction to test for SARS-CoV-2 genes from nasopharyngeal swab samples, according to the World Health Organization (WHO) interim guidance 14 .

The diagnosis of T2DM was determined using clinical records according to the WHO diagnostic criteria for T2DM 15 .

The study protocol was approved by the WRCH Ethics Committee and written informed consent was obtained from the patients included in the study.

Clinical and outcome data were reviewed and collected from electronic medical records by a trained team of physicians. The data from the medical records included demographic information, medical history, clinical characteristics, laboratory results, treatments, duration of hospital stay, and outcomes. Our main outcome was mortality among patients with COVID-19 and T2DM. Patient information was de-identi ed for privacy and con dentiality. Two independent researchers reviewed the database for accuracy.

Chi-squared test and Fisher's exact test were used to compare univariate differences between survivors and non-survivors.

Univariate logistic regression models were used to analyze effects of continuous variables on mortality. Multivariate logistic regression models were also used to assess simultaneous effects of continuous, binomial and categorical variables on survivability or mortality. Statistical signi cance was set at α (p-value) of less than 0.05. Statistical analyses were performed using the R programming language or MATLAB ®.

We have previously reported the characteristics of a cohort of 131 COVID-19 patients with T2DM measured at admission, including age, BMI, serum glucose concentration, and oxygen saturation 6 . These patients were managed with one or more diabetes medications, including insulin, metformin, sulfonylureas, and acarbose, or without any medications (Table 1 ; Fig. 1A , B). While most patients continued on the same drug(s) they had been taking, a minority of patients changed medication after admission (Fig. 1A , B).

To study the effects of diabetes medications during hospitalization on the outcome of COVID-19 patients with T2DM, we analyzed the same cohort of 131 patients using mortality as a dependent variable and medications as independent variables. When medication use after admission was analyzed for this cohort of patients, signi cant associations with survival were found for both metformin (p = 0.02) and acarbose use (p = 0.04), but not for insulin, and sulfonylurea (Table 1) .

After admission to the hospital, patients were continued with their outpatient Insulin and oral agents. In addition, some patients received new medications for diabetes, such as insulin, sulfonylureas, and acarbose, while the number of patients on metformin remained unchanged (Fig. 1A , B; Table 1 ). Among the 57 patients who used acarbose after admission, 52 survived (91.2%), and 5 (8.8%) did not survive. This nding was signi cantly different (p = 0.04) from those not on acarbose, with 18 (24.3%) deaths and 56 (75.7%) recoveries ( Table 1) , suggesting that, similar to metformin, acarbose use during hospitalization for COVID-19 was also associated with survival bene t.

Since some of these patients used more than one medication, we sought to determine if using a combination of any two diabetes medications carries bene ts for survival. To this end, we examined survival of this cohort of patients on two of the four diabetes medications before and after admission, comparing with those who were not on either of the two drugs. We found that patients who used both metformin and acarbose, but none of any other combinations, had signi cantly better chance of survival both before and after admission. Of the 131 patients of COVID-19 with diabetes, 14 were using both metformin and acarbose with or without other diabetes medications before admission. All of these 14 patients survived (100%), which was signi cantly different (p = 0.033) when compared with the 70 patients who were not on either metformin or acarbose, of whom 18 (25.7%) died and 52 (74.3%) survived (Table 2 ). After admission, more patients used acarbose, and a total of 20 patients used both metformin and acarbose, while 57 used neither. Of the 20 dual-use patients, one (5.0%) died and 19 (95.0%) survived, which is signi cantly different (p = 0.030) from the 57 who used neither [of which 17 (29.8%) died and 40 (70.2%) survived] ( Table 2 ).

The effects of combined metformin and acarbose use on survival were further analyzed using Kaplan-Meier curves and the log-rank statistics. Those taking metformin or acarbose or both were found to have signi cantly better chance of survival when compared with those on neither metformin nor acarbose either before (Fig. 1C ) or after admission (Fig. 1D ). In addition, the COVID-19 patients with T2DM taking any one of the four medications either before and after admission had signi cantly better chance of survival than those who did not take any of the four medications (Fig. 1E, F) .

The effect of combined metformin and acarbose on survival is independent of other known confounders

To determine whether any of these confounding factors were disproportionately distributed in patients taking metformin or acarbose or both, thus skewing their effects, we carried out analysis of covariance for patients grouped by taking either metformin or acarbose, or both or neither. We found that there were no signi cant differences in the distribution of these confounding factors in different groups of patients as mentioned above, except for HbA1c (Table 3) . Patients taking metformin alone or with acarbose had signi cantly higher levels of HbA1c than those taking neither drugs (Table 3 ; also see refs). However, higher levels of HbA1c were adversely associated with survival, as we have previously shown 6 . Thus, the bene cial effects of taking both metformin with or without acarbose on survival were not attributable to the differences in HbA1c levels in these patients. In addition, signi cant differences were found in the distribution of patients taking or not taking sulfonylureas among these four groups of patients taking different combinations of metformin and acarbose (Table 3 ). In this case, the differences were due to more patients not taking any drugs (49), and an imbalance between patients taking sulfonylureas and acarbose (12) vs. those taking sulfonylureas and metformin (3), whereas the same number of sulfonylureas-taking patients (8 each) who also took both metformin and acarbose as those who took none of these two drugs (Table 3 ). Since patients taking sulfonylureas alone or with either acarbose or metformin were not signi cantly associated with better survival (Table 1 , 2), we interpret that additional use of sulfonylureas does not seem to be associated with survival bene ts to patients taking metformin or acarbose or both.

Other factors we have previously found signi cantly associated with survival of this cohort of patients were not signi cantly differently distributed in patients taking metformin or acarbose or both vs those taking neither. These factors include age, BMI, glucose, triglyceride, CRP, D-dimer, and steroid use ( Table 2 , 3). Discussion COVID-19 has had a major global impact and our therapeutic strategies are still limited. This retrospective study aims to evaluate existing medications for possible repurposing. Our study of a cohort of COVID-19 patients with T2DM indicates that use of metformin and acarbose together both prior to hospitalization and during treatment in hospital is signi cantly associated with lower mortality in COVID-19 patients with T2DM. This nding should provide a basis for designing randomized, controlled clinical trials testing the effects of use of metformin or acarbose or both on COVID-19 patients with or without T2DM.

COVID-19 has spread globally with heavy impact on most countries, yet despite many ongoing and concluded clinical trials, we are still limited in therapies. The anti-viral drug remdesivir is perhaps the most promising agent, yet it has shown rather modest bene ts 1, 16 . Thus, there is need for alternative or adjunctive therapies to combat COVID-19. There have been trials of hydroxychloroquine with or without azithromycin 17, 18 and tocilizumab 19 , an antibody that inhibits interleukin-6 receptor any outcome bene ts to date.

We have recently reported that metformin use prior to hospital admission is associated with reduced mortality for COVID-19 patients with diabetes 6 , suggesting metformin as a potential COVID-19 therapeutic. We have previously shown for this cohort of 131 patients that age, body weight, BMI, oxygen desaturation, glucose, triglyceride, C-reactive protein (CRP), Ddimer levels, and steroid use were signi cantly associated with mortality 6 , consistent with reports of other cohorts of COVID-19 patients 3 . Metformin is a widely available safe and inexpensive drug that has been suggested for use in various clinical settings other than diabetes 24 . This study has found that acarbose, used alone or together with metformin during treatment, is associated with reduced mortality of COVID-19 patients with T2DM. Acarbose is another inexpensive drug that is widely used at least in China. Since metformin or acarbose alone is bene cial, taking both might have additive or even synergistic effects. Whether the combination of metformin and acarbose is effective treatment should await future randomized trials. These analyses suggest that use of metformin or acarbose or both is associated with improved survival of COVID-19 patients with T2DM independent of their effects on lowering glucose concentration and body weight.

As with all retrospective studies, the current study has limitations. First, the sample size is modest and not large enough for propensity score matching in covariate analysis. Although we have controlled for known confounders in the data analyses, there may still be residual confounding. However, given the magnitude of the survival differences we have observed, we doubt some unrecognized covariate would have such a major impact. Nonetheless we welcome further data to con rm or refute our ndings. Second, T2DM patients taking metformin or acarbose or both might have different disease severity or vulnerability than those under other management. Nonetheless, these new observations may be important and could be a basis for a more de nitive randomized trial regarding pharmacotherapy for inpatient DM in COVID-19.

The optimal therapy for inpatients with DM and COVID-19 is unclear. Our ndings support the investigation of oral agents for glucose control in this context given a potential impact on clinical outcomes. 

Remdesivir for the Treatment of Covid-19 -Final Report

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Severe Covid-19

Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19

Management of diabetes and hyperglycemia in hospitals

Standards of medical care for type 2 diabetes in China

Clinical practice. Glycemic control in the ICU

Intensive insulin in intensive care

The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus

Analyses of gut microbiota and plasma bile acids enable strati cation of patients for antidiabetic treatment

Towards effective diagnostic assays for COVID-19: a review

Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Effective treatment of severe COVID-19 patients with tocilizumab

E cacy of Tocilizumab in Patients Hospitalized with Covid-19

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53